Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2021 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day

CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
March 17, 2021 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...
March 15, 2021 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
February 16, 2021 09:00 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development

Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:...
January 07, 2021 08:00 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs

FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Praxis...
December 01, 2020 07:00 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines Announces CFO Transition

CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
November 20, 2020 08:00 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
November 17, 2020 07:45 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder

- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 - CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a...
November 09, 2020 20:00 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
October 20, 2020 16:05 ET | Source: Praxis Precision Medicines, Inc

Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...